Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

May Shawi

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
ACR Open Rheumatology|March 7, 2023
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 StudiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
RMD Open|October 29, 2015
Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian populationBoulos Haraoui, Algis Jovaisas, William G Bensen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2021
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Rheumatology and Therapy|February 22, 2024
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic ArthritisJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Arthritis Care & Research|January 29, 2014
Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registryCarter Thorne, William G Bensen, Denis Choquette, et al.
Clinical Rheumatology|March 13, 2024
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritisProton Rahman, Iain B McInnes, Atul Deodhar, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Rheumatology (Oxford, England)|June 29, 2022
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritisLaura C Coates, Christopher T Ritchlin, Laure Gossec, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
ACR Open Rheumatology|March 7, 2023
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 StudiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
RMD Open|October 29, 2015
Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian populationBoulos Haraoui, Algis Jovaisas, William G Bensen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2021
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Rheumatology and Therapy|February 22, 2024
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic ArthritisJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Arthritis Care & Research|January 29, 2014
Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registryCarter Thorne, William G Bensen, Denis Choquette, et al.
Clinical Rheumatology|March 13, 2024
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritisProton Rahman, Iain B McInnes, Atul Deodhar, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Rheumatology (Oxford, England)|June 29, 2022
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritisLaura C Coates, Christopher T Ritchlin, Laure Gossec, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Pageof 5